

Christine Spitzweg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9733411/publications.pdf>

Version: 2024-02-01

64
papers

1,941
citations

257450

24
h-index

276875

41
g-index

64
all docs

64
docs citations

64
times ranked

2090
citing authors

#	ARTICLE	IF	CITATIONS
1	The sodium iodide symporter: its pathophysiological and therapeutic implications. <i>Clinical Endocrinology</i> , 2002, 57, 559-574.	2.4	160
2	The Sodium Iodide Symporter and Its Potential Role in Cancer Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3327-3335.	3.6	117
3	Epidermal Growth Factor Receptor-targeted ¹³¹ I-therapy of Liver Cancer Following Systemic Delivery of the Sodium Iodide Symporter Gene. <i>Molecular Therapy</i> , 2011, 19, 676-685.	8.2	99
4	Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. <i>European Journal of Endocrinology</i> , 2016, 175, 521-529.	3.7	90
5	Image-guided, Tumor Stroma-targeted ¹³¹ I Therapy of Hepatocellular Cancer After Systemic Mesenchymal Stem Cell-mediated NIS Gene Delivery. <i>Molecular Therapy</i> , 2011, 19, 1704-1713.	8.2	78
6	Genetics and phenomics of hypothyroidism and goiter due to NIS mutations. <i>Molecular and Cellular Endocrinology</i> , 2010, 322, 56-63.	3.2	69
7	Mesenchymal Stem Cell-Mediated, Tumor Stroma-Targeted Radioiodine Therapy of Metastatic Colon Cancer Using the Sodium Iodide Symporter as Theranostic Gene. <i>Journal of Nuclear Medicine</i> , 2015, 56, 600-606.	5.0	66
8	Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene. <i>Clinical Cancer Research</i> , 2009, 15, 6079-6086.	7.0	65
9	Image-Guided Radioiodide Therapy of Medullary Thyroid Cancer After Carcinoembryonic Antigen Promoter-Targeted Sodium Iodide Symporter Gene Expression. <i>Human Gene Therapy</i> , 2007, 18, 916-924.	2.7	64
10	Leveraging the immune system to treat advanced thyroid cancers. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 469-481.	11.4	58
11	Application of ¹⁸⁸ Rhenium as an Alternative Radionuclide for Treatment of Prostate Cancer after Tumor-Specific Sodium Iodide Symporter Gene Expression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4451-4458.	3.6	56
12	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 404-415.	11.4	56
13	Gene Therapy for Thyroid Cancer: Current Status and Future Prospects. <i>Thyroid</i> , 2004, 14, 424-434.	4.5	52
14	Image-Guided Tumor-Selective Radioiodine Therapy of Liver Cancer After Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene. <i>Human Gene Therapy</i> , 2011, 22, 1563-1574.	2.7	44
15	Sodium Iodide Symporter (NIS)-Mediated Radionuclide (¹³¹ I, ¹⁸⁸ Re) Therapy of Liver Cancer After Transcriptionally Targeted Intratumoral <i>in Vivo</i> NIS Gene Delivery. <i>Human Gene Therapy</i> , 2011, 22, 1403-1412.	2.7	44
16	Stromal Targeting of Sodium Iodide Symporter Using Mesenchymal Stem Cells Allows Enhanced Imaging and Therapy of Hepatocellular Carcinoma. <i>Human Gene Therapy</i> , 2013, 24, 306-316.	2.7	44
17	Thyroid hormones and tetraac: new regulators of tumour stroma formation via integrin $\alpha 3 \beta 1$. <i>Endocrine-Related Cancer</i> , 2015, 22, 941-952.	3.1	41
18	Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 459-469.	4.5	37

#	ARTICLE	IF	CITATIONS
19	Harnessing mesenchymal stem cell homing as an anticancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1079-1092.	3.1	36
20	Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. <i>Oncotarget</i> , 2017, 8, 33393-33404.	1.8	33
21	Hypoxia-targeted ¹³¹ I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery. <i>Oncotarget</i> , 2016, 7, 54795-54810.	1.8	31
22	Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 263-272.	2.5	30
23	Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene. <i>Molecular Therapy</i> , 2016, 24, 1395-1404.	8.2	30
24	Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1637-1647.	2.5	29
25	Sodium Iodide Symporter (NIS) and Thyroid. <i>Hormones</i> , 2002, 1, 22-34.	1.9	27
26	Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 145-158.	5.7	23
27	Integrin α _v β ₃ -Mediated Effects of Thyroid Hormones on Mesenchymal Stem Cells in Tumor Angiogenesis. <i>Thyroid</i> , 2019, 29, 1843-1857.	4.5	23
28	Dual-targeted NIS polyplexes as a theranostic strategy toward tumors with heterogeneous receptor expression. <i>Gene Therapy</i> , 2019, 26, 93-108.	4.5	22
29	A Novel Approach for Image-Guided ¹³¹ I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery. <i>Molecular Cancer Research</i> , 2019, 17, 310-320.	3.4	22
30	Reintroducing the Sodium Iodide Symporter to Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2017, 27, 1534-1543.	4.5	21
31	External Beam Radiation Therapy Enhances Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter Gene Delivery. <i>Human Gene Therapy</i> , 2018, 29, 1287-1300.	2.7	21
32	Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes. <i>Journal of Gene Medicine</i> , 2017, 19, e2957.	2.8	20
33	Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (NIS) gene expression using a heat-inducible gene promoter in engineered mesenchymal stem cells. <i>Theranostics</i> , 2020, 10, 4490-4506.	10.0	19
34	EGFR Targeting and Shielding of pDNA Lipopolyplexes via Bivalent Attachment of a Sequence-Defined PEG Agent. <i>Macromolecular Bioscience</i> , 2018, 18, 1700203.	4.1	18
35	Radiation-Induced Amplification of TGF β 1-Induced Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter (NIS) Gene ¹³¹ I Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5997-6008.	7.0	18
36	EGFR-targeted nonviral NIS gene transfer for bioimaging and therapy of disseminated colon cancer metastases. <i>Oncotarget</i> , 2017, 8, 92195-92208.	1.8	18

#	ARTICLE	IF	CITATIONS
37	Influence of Defined Hydrophilic Blocks within Oligoaminoamide Copolymers: Compaction versus Shielding of pDNA Nanoparticles. <i>Polymers</i> , 2017, 9, 142.	4.5	17
38	TGFB1-driven mesenchymal stem cell-mediated NIS gene transfer. <i>Endocrine-Related Cancer</i> , 2019, 26, 89-101.	3.1	16
39	Regional Hyperthermia Enhances Mesenchymal Stem Cell Recruitment to Tumor Stroma: Implications for Mesenchymal Stem Cell-Based Tumor Therapy. <i>Molecular Therapy</i> , 2021, 29, 788-803.	8.2	16
40	FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. <i>Frontiers in Endocrinology</i> , 2021, 12, 712107.	3.5	16
41	Identification and characterization of myocardial metastases in neuroendocrine tumor patients using ⁶⁸ Ga-DOTATATE PET-CT. <i>Cancer Imaging</i> , 2018, 18, 34.	2.8	15
42	¹⁸ F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib. <i>Cancers</i> , 2021, 13, 317.	3.7	15
43	Long-term outcome of rare oncocytic papillary (H ¹⁴ rthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2526-2535.	6.4	14
44	Clinical impact of follicular oncocytic (H ¹⁴ rthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 449-460.	6.4	14
45	¹²⁴ I-PET Assessment of Human Sodium Iodide Symporter Reporter Gene Activity for Highly Sensitive In Vivo Monitoring of Teratoma Formation in Mice. <i>Molecular Imaging and Biology</i> , 2015, 17, 874-883.	2.6	12
46	Tetrac as an anti-angiogenic agent in cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, R287-R304.	3.1	12
47	Hypofractionated Radiotherapy for Anaplastic Thyroid Cancer: Systematic Review and Pooled Analysis. <i>Cancers</i> , 2020, 12, 2506.	3.7	11
48	Real world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. <i>Thyroid</i> , 2021, 31, 1531-1541.	4.5	11
49	Selective sodium iodide symporter (NIS) gene therapy of glioblastoma mediated by EGFR-targeted lipopolyplexes. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 432-446.	4.4	11
50	The added diagnostic value of complementary gadoxetic acid-enhanced MRI to ¹⁸ F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma. <i>Cancer Imaging</i> , 2019, 19, 73.	2.8	10
51	Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2239-e2246.	3.6	10
52	The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy. <i>EJNMMI Research</i> , 2022, 12, 25.	2.5	10
53	Effects of the Minimal Extrathyroidal Extension on Early Response Rates after (Adjuvant) Initial Radioactive Iodine Therapy in PTC Patients. <i>Cancers</i> , 2020, 12, 3357.	3.7	8
54	Thyroid Hormone Effects on Mesenchymal Stem Cell Biology in the Tumour Microenvironment. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 462-468.	1.2	7

#	ARTICLE	IF	CITATIONS
55	The diagnostic challenge of coexistent sarcoidosis and thyroid cancer – a retrospective study. <i>BMC Cancer</i> , 2021, 21, 139.	2.6	7
56	Integrin α 2 β 3-dependent thyroid hormone effects on tumour proliferation and vascularisation. <i>Endocrine-Related Cancer</i> , 2020, 27, 685-697.	3.1	7
57	Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series. <i>Clinical Endocrinology</i> , 2022, 96, 847-856.	2.4	7
58	An unusual case of struma ovarii. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2021, 2021, .	0.5	5
59	Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer. <i>In Vivo</i> , 2021, 35, 461-465.	1.3	4
60	Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 3231.	2.4	2
61	Course of Disease and Clinical Management of Patients with Poorly Differentiated Thyroid Carcinoma. <i>Cancers</i> , 2021, 13, 5309.	3.7	2
62	Preoperative Imaging with [18F]-Fluorocholine PET/CT in Primary Hyperparathyroidism. <i>Journal of Clinical Medicine</i> , 2022, 11, 2944.	2.4	1
63	Taking Advantage of the TGF β 1 Biology in Differentiated Thyroid Cancer to Stimulate Sodium Iodide Symporter (NIS)-Mediated Iodide Uptake in Engineered Mesenchymal Stem Cells. <i>Journal of the Endocrine Society</i> , 2021, 5, A1033-A1033.	0.2	0
64	SUN-120 Regional Hyperthermia Enhances Selective Mesenchymal Stem Cell Migration Towards the Tumor Stroma. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0